Humana to Exit MA Plans for 2027

Humana announced plans to exit Medicare Advantage plans in 2027 that will affect approximately 600,000 members, marking the second consecutive year the insurer has withdrawn from select markets as part of its broader Humana Medicare Advantage exits 2027 strategy to restore profitability.

What Drove This Humana Medicare Advantage Exits 2027 Decision

The Louisville-based insurer disclosed the decision during its second-quarter earnings call on July 29, 2026, saying it will shed about 8% of its 7.2 million Medicare Advantage members by exiting its least profitable plans and markets. CFO Celeste Mellet described the approach as cutting off the lower tail of profitability rather than reducing benefits uniformly across the company’s entire portfolio.

The Margin Target Behind This Strategy

Humana’s primary goal is returning to a sustainable margin of at least 3% by 2028, a target the company considers essential to long-term competitiveness. The insurer’s second-quarter pre-tax margin stood at just 1.8%, down sharply from 6.7% in 2020, reflecting the scale of profitability erosion driving this decision.

How Many Members Humana Expects to Recapture

Despite the exits, Humana expects to recapture roughly 40% of affected members, about 240,000 people, by enrolling them in other company plans that generate stronger returns. This recapture strategy suggests Humana views the exits less as an outright reduction in its overall member base and more as a redistribution toward more profitable products within its own portfolio.

Why Star Ratings Add to This Pressure

Humana’s profitability has also been strained by lower quality bonus payments tied to CMS Star Ratings, and the company has been litigating its Star Ratings calculations, arguing the methodology is overly complex and subject to unpredictable changes. A single half-star change can equate to hundreds of millions of dollars in lost quality bonus payments for a single plan.

How This Fits a Broader Medicare Advantage Industry Retrenchment

Humana’s plan exits are part of a broader industry pattern, with about 10% of the Medicare Advantage market forced to find new plans in 2026 as multiple insurers, including UnitedHealth and Aetna, withdrew from unprofitable markets. Industry observers attribute these exits to elevated medical costs, particularly among older beneficiaries using more expensive care following the pandemic, combined with regulatory payment pressures.

A Notable Contrast With Humana’s Recent Growth

This retrenchment stands in contrast to Humana’s own aggressive enrollment growth, with the company reporting a 25% increase in individual Medicare Advantage membership in 2026 over 2025, driven partly by more generous benefits than competitors offered. Those same generous offerings, however, have pressured margins, prompting this recalibration toward profitability.

What Affected Members Should Expect From This Humana Medicare Advantage Exits 2027 Plan

Members affected by the 2027 exits will receive notification letters in September and will have an enrollment window to switch to alternative coverage. Humana has emphasized that other plan options will be available, though finding comparable coverage with the same benefit levels may prove challenging in some markets.

How Humana Is Pursuing Margin Recovery Beyond These Exits

Humana is also expanding its CenterWell health services division, which reported 27% membership growth in CenterWell Senior Primary Care, and has recently acquired primary care providers including The Villages Health in Florida and MaxHealth, moves aimed at shifting seniors toward higher-quality, lower-cost value-based care arrangements.

What This Humana Medicare Advantage Exits 2027 Plan Means Going Forward

With affected members set to receive notification letters in September, the coming months will reveal how effectively Humana’s 40% recapture target holds up once beneficiaries actually begin evaluating their alternative coverage options. Given the parallel expansion of CenterWell and recent primary care acquisitions, Humana’s broader strategy suggests it is pursuing margin recovery through both narrowing its least profitable MA business and growing higher-margin value-based care simultaneously.

What to Watch Going Forward

As Humana works toward its 2028 margin target, industry observers will likely watch whether the company’s Star Ratings litigation with CMS produces any methodology changes that could ease future quality bonus payment volatility. Given the broader pattern of MA market retrenchment among UnitedHealth, Aetna, and now Humana, this Humana Medicare Advantage exits 2027 decision may continue to reflect an industry-wide recalibration toward profitability that could reshape competitive dynamics across the Medicare Advantage market heading into 2028.